ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing novel immune-based products to treat cancer. Designed to harness both arms of the native immune system, our pipeline includes both active immunotherapies and patented monoclonal antibodies. Our active immunotherapies target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our strategy is to focus primarily on the development of cancer stem cell therapeutics. We intend to work with partners to develop and commercialize our broadly applicable monoclonal antibodies. We believe our promising clinical programs, strong intellectual property, proprietary discovery technology, high-profile partnerships, and experienced leadership have the potential to create meaningful value for our stakeholders.

IMUC

Last trade:

2.56

Day's change:

0.01

Trade date:

"5/17/2013"

Trade time:

"4:01pm"

Opening:

2.60

Day's Range:

2.54 - 2.60

Volume:

307302